Post‐Diagnosis HCV RNA Testing Rates Prior to HCV Treatment Among People Living With HIV With HCV Antibody Positivity in the Asia‐Pacific Region
- 8 August 2024
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 31 (11) , 686-699
Abstract
HCV RNA test determines current active infection and is a requirement prior to initiating HCV treatment. We investigated trends and factors associated with post‐diagnosis HCV RNA testing rates prior to HCV treatment, and risk factors for first positive HCV RNA among people living with HIV (PLHIV) with HCV in the Asia‐Pacific region. PLHIV with positive HCV antibody and in follow‐up after 2010 were included. Patients were considered HCV‐antibody positive if they ever tested positive for HCV antibody (HCVAb). Repeated measures Poisson regression model was used to analyse factors associated with post‐diagnosis HCV RNA testing rates from positive HCVAb test. Factors associated with time to first positive HCV RNA from positive HCVAb test were analysed using Cox regression model. There were 767 HCVAb positive participants included (87% from LMICs) of whom 11% had HCV RNA tests. With 163 HCV RNA tests post positive HCVAb test, the overall testing rate was 5.05 per 100 person‐years. Factors associated with increased testing rates included later calendar years of follow‐up, HIV viral load ≥1000 copies/mL and higher income countries. Later calendar years of follow‐up, ALT >5 times its upper limit of normal, and higher income countries were associated with shorter time to first positive HCV RNA test. Testing patterns indicated that uptake was predominantly in high income countries possibly due to different strategies used to determine testing in LMICs. Expanding access to HCV RNA, such as through lower‐cost point of care assays, will be required to achieve elimination of HCV as a public health issue.Keywords
This publication has 19 references indexed in Scilit:
- Viral hepatitis and the cascade of care among people living with HIV in the Asia‐PacificHIV Medicine, 2022
- Feasibility, effectiveness and cost of a decentralized HCV care model among the general population in Delhi, IndiaLiver International, 2021
- Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South KoreaJournal of Gastroenterology and Hepatology, 2021
- Hepatitis C Virus Elimination by 2030: Conquering Mount ImprobableClinical Liver Disease, 2020
- Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and IncomeValue in Health, 2020
- Innovations in Hepatitis C Screening and TreatmentHepatology Communications, 2020
- Global timing of hepatitis C virus elimination in high‐income countriesLiver International, 2019
- A pseudo-random patient sampling method evaluatedJournal of Clinical Epidemiology, 2017
- Cost‐effectiveness of strategies for testing current hepatitis C virus infectionHepatology, 2015
- Trends in HCV RNA Testing Among HCV Antibody-Positive Persons in Care, 2003-2010Clinical Infectious Diseases, 2014